WCM Investment Management LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

WCM Investment Management LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 57.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 213,157 shares of the company's stock after acquiring an additional 77,403 shares during the period. WCM Investment Management LLC's holdings in Teva Pharmaceutical Industries were worth $3,214,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Ion Asset Management Ltd. grew its holdings in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock valued at $807,766,000 after buying an additional 409,778 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after acquiring an additional 489,041 shares during the last quarter. Duquesne Family Office LLC increased its stake in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after acquiring an additional 7,569,450 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Teva Pharmaceutical Industries by 40.6% during the 4th quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company's stock worth $148,497,000 after acquiring an additional 1,945,688 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Up 2.6%

Shares of NYSE TEVA opened at $17.07 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The stock has a market cap of $19.58 billion, a P/E ratio of -14.84, a PEG ratio of 0.85 and a beta of 0.60. The business's fifty day simple moving average is $16.90 and its 200-day simple moving average is $17.39. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company's revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $0.48 EPS. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TEVA. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $24.13.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.